ライフサイエンスコーパス: steroidal anti-inflammatory drug

1 resence and absence of diclofenac (DCF), non-steroidal anti-inflammatory drug.

2 ioselective oxidation of several anionic non-steroidal anti-inflammatory drugs.

3 m for chemoprevention of colon cancer by non-steroidal anti-inflammatory drugs.

4 adequate response or contraindication to non-steroidal anti-inflammatory drugs.

5 available therapies, such as opioids or non-steroidal anti-inflammatory drugs.

6 es, antidiabetic thiazolidinediones, and non-steroidal anti-inflammatory drugs.

7 s and is one of the principle targets of non-steroidal anti-inflammatory drugs.

8 ve protein and an inadequate response to non-steroidal anti-inflammatory drugs.

9 rs are Helicobacter pylori infection and non-steroidal anti-inflammatory drugs.

10 esults against gastric damage induced by non-steroidal anti-inflammatory drugs.

11 wo or intolerance or contraindication to non-steroidal anti-inflammatory drugs.

12 s the principal target for the action of non-steroidal anti-inflammatory drugs.

13 a target for the development of specific non-steroidal anti-inflammatory drugs.

14 ), anxiety (1.2%), and prescriptions for non-steroidal anti-inflammatory drugs (1.2%).

15 Pretreatment with the non-steroidal anti-inflammatory drug, 2-cyano-3,12-dioxoolea

16 lumiracoxib (59 events [0.65%]) and the non-steroidal anti-inflammatory drugs (50 events [0.55%]; ha

17 ations was 1.09% (95% CI 0.82-1.36) with non-steroidal anti-inflammatory drugs (64 events) versus 0.2

18 antial evidence that binding of heme and non-steroidal anti-inflammatory drugs alters the conformatio

19 nesthetics, ketamine, acetaminophen, and non-steroidal anti-inflammatory drugs) analgesic drugs can m

20 population, 0.55% (50/9127) of those on non-steroidal anti-inflammatory drugs and 0.65% (59/9117) of

21 For other antibiotics, non-steroidal anti-inflammatory drugs and other drugs, skin

22 This might be a result of the use of non-steroidal anti-inflammatory drugs and rheumatoid agents

23 Non-selective (e.g. non-steroidal anti-inflammatory drugs) and selective cycloox

24 genase site, which is the target for the non-steroidal anti-inflammatory drugs, and a spatially disti

25 roenteritis, female sex, smoking, use of non-steroidal anti-inflammatory drugs, and Helicobacter pylo

26 Unlike antipyretic non-steroidal anti-inflammatory drugs, APAP elicits hypother

27 Although Helicobacter pylori and use of non-steroidal anti-inflammatory drugs are common causes, dem

28 optimal, but combinations of opioids and non-steroidal anti-inflammatory drugs are helpful.

29 tive blood loss after tonsillectomy when non-steroidal anti-inflammatory drugs are used.

30 Non-steroidal anti-inflammatory drugs are widely used for th

31 The non-steroidal anti-inflammatory drug aspirin and its metabol

32 obacter pylori (H. pylori) infection and non-steroidal anti-inflammatory drugs/aspirin use are the wi

33 H. pylori infection and cautious use of non-steroidal anti-inflammatory drugs/aspirin.

34 Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tu

35 omplications compared with non-selective non-steroidal anti-inflammatory drugs, but evidence is limit

36 ic diarrhea, we found use of aspirin and non-steroidal anti-inflammatory drugs, but not other implica

37 and analgesic properties to traditional non-steroidal anti-inflammatory drugs, but with significantl

38 that the carboxylate group of an acidic non-steroidal anti-inflammatory drug can bind to a COX enzym

39 ement for a cofactor (exercise, alcohol, non-steroidal anti-inflammatory drugs, Cannabis sativa) to b

40 the late-stage functionalization of the non-steroidal anti-inflammatory drug celecoxib.

41 ings are sufficient to discuss potential non-steroidal anti-inflammatory drug cessation in patients n

42 ow that fatty acids, prostaglandins, and non-steroidal anti-inflammatory drugs, compounds that are su

43 cancer, and is a key molecular target of non-steroidal anti-inflammatory drugs, compounds that reduce

44 Higher age, BMI and prescription of non-steroidal anti-inflammatory drugs contributed most to in

45 Other agents, such as aspirin, other non-steroidal anti-inflammatory drugs, COX-2 inhibitors, ret

46 tments have been suggested, ranging from non-steroidal anti-inflammatory drugs, drugs for neuropathic

47 Evidence that chronic intake of non-steroidal anti-inflammatory drugs, especially aspirin, p

48 nd in the subgroups with/without asthma; non-steroidal anti-inflammatory drug-exacerbated respiratory

49 andomisation was stratified by asthma or non-steroidal anti-inflammatory drug-exacerbated respiratory

50 a cobalt(III)-cyclam complex bearing the non-steroidal anti-inflammatory drug, flufenamic acid is rep

51 etic acid, a defluorinated analog of the non-steroidal anti-inflammatory drug flurbiprofen.

52 eatment, we examined the efficacy of the non-steroidal anti-inflammatory drug, flurbiprofen, to suppr

53 ium-oxide nanoparticles (nanoceria) as a non-steroidal anti-inflammatory drug for endometriosis thera

54 c drugs (DMARDs), or at least 4 weeks of non-steroidal anti-inflammatory drugs for psoriatic arthriti

55 ATB-346 is a hydrogen sulfide-releasing non-steroidal anti-inflammatory drug (H(2) S-NSAID) derived

56 A new generation of non-steroidal anti-inflammatory drugs has been described tha

57 t individuals taking aspirin and related non-steroidal anti-inflammatory drugs have reduced risk of l

58 Topical non-steroidal anti-inflammatory drugs have the potential to

59 (DOX) and carprofen (CPF), a veterinary non-steroidal anti-inflammatory drug, have synergistic antim

60 to 70%-80% of patients with a suspected non-steroidal anti-inflammatory drug hypersensitivity (NSAID

61 recursors and higher than the well-known non-steroidal anti-inflammatory drug ibuprofen.

62 investigated potential therapy with the non-steroidal anti-inflammatory drug ibuprofen.

63 t unlike that caused by solutions of the non-steroidal anti-inflammatory drug ibuprofen.

64 is a toxic transformation product of the non-steroidal, anti-inflammatory drug ibuprofen.

65 systemic antibiotic (doxycycline) and a non-steroidal anti-inflammatory drug (ibuprofen), administer

66 y observed lack of efficacy of classical non-steroidal anti-inflammatory drugs in the treatment of hy

67 ective detection of meclofenamic acid, a non-steroidal anti-inflammatory drug, in dairy products.

68 e blockade, and further investigation of non-steroidal anti-inflammatory drugs, in the chemopreventio

69 Non-steroidal anti-inflammatory drugs inhibit PG synthesis v

70 diuretics, antivirals, methotrexate, and non-steroidal anti-inflammatory drugs) is organic anion tran

71 ecretase modulators (GSMs), such as some non-steroidal anti-inflammatory drugs, is a promising therap

72 lation of serine 121 in cells exposed to non-steroidal anti-inflammatory drugs leads to HSP90 dissoci

73 ve consistently demonstrated that common non-steroidal anti-inflammatory drugs may protect against th

74 A subset of non-steroidal anti-inflammatory drugs modulates the gamma cl

75 n pharmacotherapies, which have included non-steroidal anti-inflammatory drugs, must take into accoun

76 e of solid formulation of anesthetic and non-steroidal anti-inflammatory drugs, namely Lidocaine and

77 was designed to determine if non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) are associa

78 Non-aspirin, non-steroidal anti-inflammatory drugs (NANSAIDs) have comple

79 f a series of novel Pt(IV) prodrugs with non-steroidal anti-inflammatory drugs naproxen, diclofenac,

80 inhibitor lumiracoxib compared with two non-steroidal anti-inflammatory drugs, naproxen and ibuprofe

81 Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topica

82 Treatment with a NO-donating non-steroidal anti-inflammatory drug (NSAID) alleviates this

83 Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygen

84 se (GERD), Barrett's esophagus (BE), and non-steroidal anti-inflammatory drug (NSAID) bleeding prophy

85 Non-steroidal anti-inflammatory drug (NSAID) exacerbated res

86 The unprecedented polymorphism of the non-steroidal anti-inflammatory drug (NSAID) flufenamic acid

87 In the non-steroidal anti-inflammatory drug (NSAID) group, patients

88 Non-steroidal anti-inflammatory drug (NSAID) ingestion over

89 s about the cardiovascular safety of the non-steroidal anti-inflammatory drug (NSAID) rofecoxib, espe

90 Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) that independen

91 ow that inhibition of endogenous PGE2 by non-steroidal anti-inflammatory drug (NSAID) treatment in mi

92 Non-steroidal anti-inflammatory drug (NSAID) treatment suppr

93 h or standard doses compared with remote non-steroidal anti-inflammatory drug (NSAID) use or celecoxi

94 and gastrointestinal damage from chronic non-steroidal anti-inflammatory drug (NSAID) use; and opioid

95 urgery and to evaluate the effect of the non-steroidal anti-inflammatory drug (NSAID), ibuprofen, on

96 associated with type 2 inflammation and non-steroidal anti-inflammatory drug (NSAID)-exacerbated res

97 Non-steroidal anti-inflammatory drug (NSAID)-exacerbated res

98 mine-gallic acid hybrid molecule against non-steroidal anti-inflammatory drug (NSAID)-induced gastrop

99 We used an animal model of non-steroidal anti-inflammatory drug (NSAID)-induced SI epit

100 eports in the literature have shown that non-steroidal anti-inflammatory drugs (NSAID) may affect oss

101 Aspirin and other non-steroidal anti-inflammatory drugs (NSAID) probably decre

102 PRP due to DR and compared analgesics or non-steroidal anti-inflammatory drugs (NSAID) to placebo.

103 ose and regularity of aspirin use, other non-steroidal anti-inflammatory drugs (NSAID), and the effec

104 Patients with Non-steroidal anti-inflammatory drugs (NSAID)-Exacerbated Re

105 y (OR = 2.35; 95%CI = 1.09-5.05), weekly non-steroidal anti-inflammatory drug (NSAIDs) intake (OR = 0

106 Certain non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., rofeco

107 (i.e., TGF-beta 1, PDGF, and IGF-1), and non-steroidal anti-inflammatory drugs (NSAIDs) (indomethacin

108 that underlie the antitumour activity of non-steroidal anti-inflammatory drugs (NSAIDs) against color

109 Numerous medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and corticost

110 stigate the effects of different topical non-steroidal anti-inflammatory drugs (NSAIDs) and demograph

111 oxicity of commonly used drugs including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids.

112 Non-steroidal anti-inflammatory drugs (NSAIDs) and other eic

113 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the

114 Non-steroidal anti-inflammatory drugs (NSAIDs) are among the

115 2 selective inhibitors and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) are associate

116 Non-steroidal anti-inflammatory drugs (NSAIDs) are inhibitor

117 Non-steroidal anti-inflammatory drugs (NSAIDs) are known gam

118 Non-steroidal anti-inflammatory drugs (NSAIDs) are known to

119 Non-steroidal anti-inflammatory drugs (NSAIDs) are used to m

120 Non-steroidal anti-inflammatory drugs (NSAIDs) are widely ov

121 As an additional pharmacologic approach, non-steroidal anti-inflammatory drugs (NSAIDs) can reduce gi

122 Non-steroidal anti-inflammatory drugs (NSAIDs) cause damage

123 COX2-selective non-steroidal anti-inflammatory drugs (NSAIDs) cause selecti

124 Non-steroidal anti-inflammatory drugs (NSAIDs) damage the ga

125 terviewed about use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) during the 7

126 Non-steroidal anti-inflammatory drugs (NSAIDs) exert their e

127 selective inhibitors versus traditional non-steroidal anti-inflammatory drugs (NSAIDs) has not been

128 The progressive consumption growth of non-steroidal anti-inflammatory drugs (NSAIDs) has progressi

129 Zinc chelation and non-steroidal anti-inflammatory drugs (NSAIDs) have been exp

130 for reducing gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs) have been sub

131 Non-steroidal anti-inflammatory drugs (NSAIDs) have been wid

132 Previous studies have shown that non-steroidal anti-inflammatory drugs (NSAIDs) have signific

133 sis (FASS) for the determination of five non-steroidal anti-inflammatory drugs (NSAIDs) in bovine mil

134 The prophylactic action of non-steroidal anti-inflammatory drugs (NSAIDs) in heterotopi

135 ios to simulate the solubility of twelve non-steroidal anti-inflammatory drugs (NSAIDs) in the superc

136 rticoid therapy, hydroxychloroquine, and non-steroidal anti-inflammatory drugs (NSAIDs) in the treatm

137 xamethasone (DEX) alone or combined with non-steroidal anti-inflammatory drugs (NSAIDs) in third mola

138 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX e

139 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo

140 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo

141 Topically administered non-steroidal anti-inflammatory drugs (NSAIDs) inhibit perio

142 Analgesia by non-steroidal anti-inflammatory drugs (NSAIDs) is ascribed t

143 Use of non-steroidal anti-inflammatory drugs (NSAIDs) is associated

144 The efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) is considered

145 elicobacter pylori in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs) is unclear.

146 trials demonstrate that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) markedly redu

147 opreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal

148 The toxicity for the human body of non-steroidal anti-inflammatory drugs (NSAIDs) overdoses is

149 inically important errors: non-selective non-steroidal anti-inflammatory drugs (NSAIDs) prescribed to

150 al evidence suggests that chronic use of non-steroidal anti-inflammatory drugs (NSAIDs) reduces the r

151 Nitric oxide (NO)-donating non-steroidal anti-inflammatory drugs (NSAIDs) represent a p

152 Furthermore, topical application of non-steroidal anti-inflammatory drugs (NSAIDs) significantly

153 Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibupr

154 ns' data to study drug interactions with non-steroidal anti-inflammatory drugs (NSAIDS) that result i

155 Non-steroidal anti-inflammatory drugs (NSAIDs) use in the ye

156 x, body mass index (BMI), antibiotics or non-steroidal anti-inflammatory drugs (NSAIDs) use, hypothes

157 Interestingly, the use of non-steroidal anti-inflammatory drugs (NSAIDs) was not assoc

158 respectively), while anti-infectives and non-steroidal anti-inflammatory drugs (NSAIDs) were frequent

159 Activity clustering showed that non-steroidal anti-inflammatory drugs (NSAIDs) were signific

160 statin drugs, low-dose aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs), and even fis

161 Non-steroidal anti-inflammatory drugs (NSAIDs), developed si

162 al trials have suggested that the use of non-steroidal anti-inflammatory drugs (NSAIDs), including as

163 jaw exercise with mobilisation, CBT with non-steroidal anti-inflammatory drugs (NSAIDS), manipulation

164 g opioid crisis highlighted the need for non-steroidal anti-inflammatory drugs (NSAIDs), nonaddictive

165 Both the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as indo

166 Non-steroidal anti-inflammatory drugs (NSAIDs), the most wid

167 reasing prevalence of individuals taking non-steroidal anti-inflammatory drugs (NSAIDs), there is con

168 Use of non-steroidal anti-inflammatory drugs (NSAIDs), which work b

169 an inadequate response or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs).

170 lta might be a target of chemopreventive non-steroidal anti-inflammatory drugs (NSAIDs).

171 the thiazolidinediones, and a variety of non-steroidal anti-inflammatory drugs (NSAIDs).

172 d compounds for the development of novel non-steroidal anti-inflammatory drugs (NSAIDs).

173 of these drugs compared with traditional non-steroidal anti-inflammatory drugs (NSAIDs).

174 ADT, regular long-term use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs; yes vs no), p

175 gs in four therapeutic areas: analgesia (non-steroidal anti-inflammatory drugs [NSAIDs]), diabetes (m

176 ects of tetracyclines, and the effect of non-steroidal anti-inflammatory drugs on decreasing alveolar

177 vity by the administration of PTH and/or non-steroidal anti-inflammatory drugs or COX-2 selective inh

178 e of such therapies precluded the use of non-steroidal anti-inflammatory drugs or other enzyme inhibi

179 tack therapies (eg, simple analgesics or non-steroidal anti-inflammatory drugs) or specific agents wi

180 d PUD was associated with current use of non-steroidal anti-inflammatory drugs, oral steroids or acid

181 ation resolved with topical steroids and non-steroidal anti-inflammatory drugs over a course of 11-24

182 olled trials of analgesic medicines (eg, non-steroidal anti-inflammatory drugs, paracetamol, opioids,

183 n deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status,

184 Evidence that aspirin and other non-steroidal anti-inflammatory drugs reduce risk for colore

185 hree classes of medications of interest: non-steroidal anti-inflammatory drugs, renin-angiotensin-ald

186 Ibuprofen, a non-steroidal anti-inflammatory drug, rescued female embryos

187 nsteroidal anti-inflammatory drugs (NSAIDs), steroidal anti-inflammatory drugs (SAIDs), immunosuppres

188 ics, antimotility agents, narcotics, and non-steroidal anti-inflammatory drugs should not be given to

189 studies have shown that long-term use of non-steroidal anti-inflammatory drugs, statins, histamine H2

190 In this study we evaluate the effect of non-steroidal anti-inflammatory drugs, such as indomethacin

191 d placebo-controlled trials, traditional non-steroidal anti-inflammatory drugs, such as naproxen, dic

192 The non-steroidal anti-inflammatory drug sulindac decreases size

193 Flufenamic acid (FFA) is a non-steroidal anti-inflammatory drug that has been long used

194 underlying detrimental kidney effects of non-steroidal anti-inflammatory drugs that inhibit cyclooxyg

195 Unlike non-steroidal anti-inflammatory drugs, the PPs do not direct

196 statin, antihypertensive medications and non-steroidal anti-inflammatory drugs therapy) as well as 4

197 should consider the pharmacokinetics of non-steroidal anti-inflammatory drugs to determine the optim

198 predictors of MC with odds ratio for any non-steroidal anti-inflammatory drug use of 3.04 (95% CI: 1.

199 He denied any alcohol or non-steroidal anti-inflammatory drug use.

200 ciated with sex, alcohol consumption, or non-steroidal anti-inflammatory drug use.

201 Oral non-steroidal anti-inflammatory drugs versus other oral anal

202 Aspirin and other non-steroidal anti-inflammatory drugs were more commonly use

203 Selective COX-2 inhibitors are non-steroidal anti-inflammatory drugs which directly target

204 Non-steroidal anti-inflammatory drugs, which inhibit the cyc

205 rmeability after chronic or acute use of non-steroidal anti-inflammatory drugs, which may be attenuat

206 treatment of AP is the administration of non-steroidal anti-inflammatory drugs, which themselves can

207 f the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemop

208 Similarly, non-steroidal anti-inflammatory drugs with the ability to ac

209 ion in ulcer complications compared with non-steroidal anti-inflammatory drugs without an increase in